medigraphic.com
Academia Mexicana de Neurología, A.C.

2007, Number 1

<< Back Next >>

Rev Mex Neuroci 2007; 8 (1)

Intrathecal IgG synthesis and blood-CSF barrier permeability in the follow up of patients with multiple sclerosis treated with biomoduline T

González-Quevedo MA, Alfaro CI, Gámez MLA, Fernández CR, Lara RRF, Rodríguez MR, Maza J

Language: Spanish
References: 24
Page: 18-22
PDF size: 397.59 Kb.


ABSTRACT

Introduction: Multiple sclerosis (MS) has been treated with various immunomodulatory drugs, among which products derived from the thymus have been considered. In the present work the results of an open, controlled clinical trial, where the efficacy of biomoduline T (BT) on the clinical course of MS and on the follow up of cerebrospinal fluid (CSF) studies is presented. Patients and methods: Nineteen clinically defined MS patients of the relapsing-remitting form, who received intravenous BT (60 mg weekly during one year), were included. Kurtzke’s Disability Status Scale (EDSS) and CSF parameters were evaluated before therapy, and at 6 and 12 months treatment. CSF variables studied were: total protein concentration, IgG Index, presence of oligoclonal bands by polyacrylamide gel eletrophoresis and blood-CSF barrier permeability. Results: After 12 months treatment clinical improvement of the patients was observed, expressed as a decrease of the EDSS score, which was not accompanied by an improvement of CSF parameters. Conclusions: Although clinical improvement was observed in MS patients treated during 12 months with BT, CSF parameters were not changed. However CSF follow up might prove useful for evaluating the efficacy of therapy after lengthier periods and/ or during the treatment of relapses.


REFERENCES

  1. Gonsette RE. La terapia combinada en la esclerosis múltiple. Cuadernos de Esclerosis Múltiple 2004; 17.

  2. Hafler DA. Multiple sclerosis. J Clin Invest 2004; 113: 788-94.

  3. Baxevanis CN, Sfagos C, Anastasopoulos E, Reclos GJ, Papamichail M. Prothymosin-alpha enhances HLA-DR antigen expression on monocytes from patients with multiple sclerosis. J Neuroimmunol 1990; 27: 141-7.

  4. Lara Rodríguez RF, Gámez Morales L, Rodríguez R, Paz Sendin L, Vargas A, Viada González C, et al. Multicenter clinical trial: Treatment of the exacerbation of multiple sclerosis with biomodulina T (1998-2003), clinical efficacy. Arquivos de Neuro-psiquiatría. Jornal Oficial da Academia Brasileira de Neurología 2004; 62(Supl 1): 36.

  5. Charles MP. Multiple sclerosis observations and reflections. A personal memoir. J Neurolog Scien 1992; 107: 127-40.

  6. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, Öhman S, Racke MK, Sharief M, Sindic CJM, Sellebjerg F, Tourtellotte WW. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis. Arch Neurol 2005; 62: 865-70.

  7. McDonald WI. Diagnosis of multiple sclerosis. BMJ 1989; 299: 635-7.

  8. Robinson Agramonte MA, Guzmeli V, Martínez Benítez M, Infante Velásquez E, Galvizo Sánchez RJ, Ochoa Zaldívar M, Robinson Agramante JE. Contribución de la detección de bandas oligoclonales (BOC) en LCR para la confirmación del diagnóstico de Esclerosis Múltiple (EM). Rev Mex Neuroci 2005; 6(1): 8-15.

  9. Tourtellotte WW, Ma B. Multiple sclerosis: the blood brain barrier and the measurement of the novo central nervous system IgG synthesis. Neurology 1978; 28: 76-83.

  10. Gámez L, Alfaro I, Fernández R, González-Quevedo A, Infante-Velázquez E, Bender del Busto JE. Algunas reflexiones sobre las formas progresivas de esclerosis múltiple. Rev Mex Neuroci 2004; 5(5): 523-4.

  11. Tourtellotte WW, Syndulko K, Baumhefner RW, Shapshak P, Osborne M. A Comprehensive protocol for clinical trial in MS which favoured azathioprine and corticosteroid as type of treatment for chronic progressive phase. Neurology 1988; 38(Suppl.): 83-5.

  12. Miller DH. The role of MRI in the diagnosis and treatment of MS patients. MS management 1995; 2-1: 36-42.

  13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.

  14. Lowry OH, Rosebrugh RJ, Farr Al, Randal RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 265-75.

  15. Ornstein L. Disc electrophoresis. Part I: Background and theory. Ann NY Acad Sci 1964; 121: 321-41.

  16. Davis BJ. Disc electrophoresis. Part II: Method and application to human serum proteins. Ann N Y Acad Sci 1964; 121: 404-27.

  17. Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 1965; 2: 235-54.

  18. Tibling G, Link H, Ohman S. Principles of albumin IgG analysis in neurological disorders. I. Establishment of reference. Scand J Clin Lab Invest 1977; 37: 385-90.

  19. Cabrera-Gómez JA, Aechazabal N, Aguilera O, Casanova M, Gómez I, Ramos AM, González-Quevedo A, Fernández R, Vals O, Rodríguez A, Cabrera Núñez JA. Esclerosis múltiple en Cuba. Estado actual y perspectivas. Rev Neurol Argentina 2000; 25(Suplem) 3: 8.

  20. Fernández R, González-Quevedo A, Alfaro I, Gámez L, Cabrera JA, Suárez I, Vicente I. Gelatinasas A y B en el líquido cefalorraquídeo de pacientes con esclerosis múltiple. Rev Neurol Argentina 2000; 25, Suplem 3.

  21. Fortini AS, Sanders EL, Weinshenker BG, Katzmann JA. Cerebrospinal fluid oligoclonal bands in the diagnosis of multiple sclerosis. Am J Clin Pathol 2003; 120(5): 672-75.

  22. Ebers GC. Oligoclonal banding in MS. Ann NY Acad Sci 1984; 436: 206-12.

  23. Poser CM. An Atlas of multiple sclerosis. New York – UK: The Parthenon Publishing Group; 1998.

  24. Amato MP, Ponziani G. A prospective study on the prognosis of multiple sclerosis. Neurol Sci 2000; 21: S831-S838.




2020     |     www.medigraphic.com